1. |
Poole KE, van Bezooijen RL, Loveridge N,et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005; 19: 1842-4.
|
2. |
Moester MJ, Papapoulos SE, Löwik CW,et al. Sclerostin: Current knowledge and future perspectives. Calcif Tissue Int 2010; 87: 99-107.
|
3. |
Terpos E, Fragiadaki K, Konsta M,et al. Early effects of IL-6 receptor inhibition on bone homeostasis: A pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol 2011; 29: 921-5.
|
4. |
Cejka D, Herberth J, Branscum AJ,et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877-82.
|
5. |
Cejka D, Jäger-Lansky A, Kieweg H,et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012; 27: 226-30.
|
6. |
Mödder UI, Hoey KA, Amin S,et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011; 26: 373-9.
|
7. |
Mirza FS, Padhi ID, Raisz LG,et al. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 2010; 95: 1991-7.
|
8. |
García-Martín A, Rozas-Moreno P, Reyes-García R,et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: 234-41.
|
9. |
Gennari L, Merlotti D, Valenti R,et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 1737-44.
|
10 |
McNulty M, Singh RJ, Li X,et al. Determination of serum and plasma sclerostin concentrations by enzyme- linked immunoassays. J Clin Endocrinol Metab 2011; 96: E1159-62.
|
11 |
Saller A, Maggi S, Romanato G,et al. Diabetes and osteoporosis. Aging Clin Exp Res 2008; 20: 280-9.
|
12 |
Mödder UI, Clowes JA, Hoey K,et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 2010; 26: 27-34.
|
13 |
Polyzos SA, Anastasilakis AD, Bratengeier C,et al. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six- month effect of risedronate and teriparatide. Osteoporos Int 2012; 23: 1171-6.
|
14 |
van Lierop AH, Witteveen JE, Hamdy NA,et al. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 2010; 163: 833-7.
|
15 |
Bergström I, Parini P, Gustafsson SA,et al. Physical training increases osteoprotegerin in postmenopausal women. J Bone Miner Metab 2012; 30: 202-7.
|